Reviva to Host KOL Event To Discuss Topline Data From Phase 3 RECOVER Trial Of Brilaroxazine In Schizophrenia
Portfolio Pulse from Benzinga Newsdesk
Reviva Pharmaceuticals Holdings, Inc. (RVPH) announced a KOL event on February 15, 2024, to discuss Phase 3 RECOVER trial results of brilaroxazine for schizophrenia. The event will feature experts Larry Ereshefsky and Mark Opler, focusing on the unmet medical need in schizophrenia treatment and brilaroxazine's potential. The trial showed positive outcomes, meeting all primary and secondary endpoints with a well-tolerated side effect profile. Brilaroxazine is also being developed for other neuropsychiatric and inflammatory diseases, having received Orphan Drug Designation for PAH and IPF.
February 06, 2024 | 1:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Reviva Pharmaceuticals announced a KOL event to discuss positive Phase 3 results of brilaroxazine for schizophrenia, indicating potential for FDA approval and expansion into other treatments.
The announcement of positive Phase 3 trial results for brilaroxazine in treating schizophrenia, along with the drug's potential application in other neuropsychiatric and inflammatory diseases, is likely to be viewed positively by investors. The successful completion of the trial and the drug's well-tolerated side effect profile could lead to FDA approval, enhancing RVPH's market position and potentially increasing its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100